Natera, Inc. NTRA Royalty — Deferred Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Natera, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The source filing: Natera, Inc.’s 10-K, filed February 27, 2026.
- Filed
- Feb 26, 2026, 7:00 PM EST
- Fiscal year
- FY2025
- Accession
- 0001104659-26-020881
The Company has a single remaining performance obligation related to oncology assay interpretation services to be provided to BGI Genomics, to which $20.0 million of transaction consideration was allocated and prepaid by BGI Genomics. During the years ended December 31, 2025 and 2024, the Company recognized $0.5 million and $1.6 million, respectively, related to oncology assay interpretation services, of which $0.5 million and $1.4 million, respectively, were recognized against deferred royalties. The Company has $16.8 million in deferred revenue as of December 31, 2025.
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Natera, Inc.'s royalty — deferred revenue?
- Natera, Inc. (NTRA) reported royalty — deferred revenue of $500K in Q4 2025.
- What does royalty — deferred revenue mean?
- This metric represents the deferred revenue or contract liability arising from royalty-based arrangements where the company has received consideration but has not yet satisfied the performance obligations. It reflects the portion of royalty-related payments that must be recognized as revenue in future periods as the underlying contractual services or milestones are delivered. This is a key indicator of future revenue potential tied to intellectual property licensing and royalty agreements.
Ask your AI about Natera, Inc.'s royalty — deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
